

**AIPL1 Antibody (N-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP12385a****Specification**

---

**AIPL1 Antibody (N-term) Blocking peptide - Product Information**

Primary Accession [Q9NZN9](#)

**AIPL1 Antibody (N-term) Blocking peptide - Additional Information**

**Gene ID** 23746

**Other Names**

Aryl-hydrocarbon-interacting protein-like 1, AIPL1, AIPL2

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**AIPL1 Antibody (N-term) Blocking peptide - Protein Information**

**Name** AIPL1

**Synonyms** AIPL2

**Function**

May be important in protein trafficking and/or protein folding and stabilization.

**Cellular Location**

Cytoplasm. Nucleus

**Tissue Location**

Highly expressed in retina. Specifically localized to the developing photoreceptor layer and within the photoreceptors of the adult retina.

**AIPL1 Antibody (N-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**AIPL1 Antibody (N-term) Blocking peptide - Images****AIPL1 Antibody (N-term) Blocking peptide - Background**

Leber congenital amaurosis (LCA) accounts for at least 5% of all inherited retinal disease and is the most severe inherited retinopathy with the earliest age of onset. Individuals affected with LCA are diagnosed at birth or in the first few months of life with severely impaired vision or blindness, nystagmus and an abnormal or flat electroretinogram. The photoreceptor/pineal-expressed gene, AIPL1, encoding aryl-hydrocarbon interacting protein-like 1, was mapped within the LCA4 candidate region. The protein contains three tetratricopeptide motifs, consistent with nuclear transport or chaperone activity. AIPL1 mutations may cause approximately 20% of recessive LCA.

**AIPL1 Antibody (N-term) Blocking peptide - References**

Pasadhika, S., et al. Invest. Ophthalmol. Vis. Sci. 51(5):2608-2614(2010) Kirschman, L.T., et al. Hum. Mol. Genet. 19(6):1076-1087(2010) Sundaresan, P., et al. Mol. Vis. 15, 1781-1787 (2009)  
:Hidalgo-de-Quintana, J., et al. Invest. Ophthalmol. Vis. Sci. 49(7):2878-2887(2008) Booij, J.C., et al. J. Med. Genet. 42 (11), E67 (2005) :